Press Releases

and/or
566 News Releases found
Memorial Sloan Kettering Is Expanding Its Footprint in Long Island

Memorial Sloan Kettering, one of the nation’s top cancer treatment and research institutions, is expanding its reach on Long Island with a new 114,000-square-foot freestanding cancer treatment center in Nassau County. Once complete, MSK Nassau will house the area’s most comprehensive cancer care program, centrally located and staffed by the most forward-thinking and compassionate healthcare teams whose sole focus is caring for people with cancer.
Norwalk Hospital and Memorial Sloan Kettering Launch Unique Cancer Care Collaboration

Norwalk Hospital and Memorial Sloan Kettering Cancer Center (MSK) today announced MSK Physicians at Norwalk Hospital, a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital.
Cancer Immunologist Andrea Schietinger of Sloan Kettering Institute Honored with Prestigious NIH Director’s New Innovator Award

Cancer immunologist Andrea Schietinger, PhD, of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award. Dr. Schietinger was selected as a winner for her groundbreaking work in immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy. A total of 55 New Innovator Awards were given out by the NIH this year.
Study Targets Gene-Guided Prevention and Treatment at the Time of Cancer Diagnosis

A new study from Kenneth Offit, MD, Chief of the Clinical Genetics Service and Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center (MSK), finds that more than half of inherited cancer gene mutations in people with advanced cancer are not detected using traditional methods based on family history.
Researchers Find Drug Combination Reduces Recurrence Risk in Patients with HER2-Positive Early Breast Cancer

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.
Dr. Monica Morrow
Study Finds Rate of Mastectomies Decreases with Adoption of Breast Tumor Margin Guidelines: What This Means in the Overtreatment Debate for Breast Cancer

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.
Dr. Mark E. Robson, MD
Phase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes in Breast Cancer

Increased progression-free survival and a better quality of life were seen in HER2-negative metastatic breast cancer patients with a BRCA mutation who were treated with olaparib versus a single-agent chemotherapy.
Dr. Ethan Basch, MD. Photo Credit: Brian Strickland/UNC Lineberger Comprehensive Cancer Center
Real-Time, Patient-Reported Symptom Monitoring Demonstrates an Overall Survival Benefit

Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of Clinical Oncology. Data showed that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes (PROs) improved overall survival.
Novel Sequencing Approach Seeks to Detect Cancer’s Genomic Alterations

Findings Could Inform the Development of a Blood Test for Early Cancer Detection
Dr. David Hyman, MD
Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

Breakthrough findings illustrate the promise of precision oncology and signify a paradigm shift in drug development. Interim data from three trials show a 76 percent confirmed overall response rate in patients treated with the TRK inhibitor.